Nilotinib (Tasigna®; Novartis, East Hanover, NJ, USA) is a BCR–ABL1 inhibitor designed to be more potent and selective than imatinib [15] and shows better efficacy than imatinib for the treatment of patients with newly diagnosed CML in chronic phase [16]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.